|
 Remember that you can order de content of the table by clicking on the title
of each column.
| Product |
Subject |
Year |
PDF |
| Racotumomab (1E10) |
Preclinic and mechanism of action |
1995 |
(1210 kb.) |
| Racotumomab (1E10) |
Preclinic and mechanism of action |
1998 |
(1230 kb.) |
| GM3/VSSP |
Preclinic and mechanism of action |
1999 |
(3150 kb.) |
| GM3/VSSP |
Preclinic and mechanism of action |
2000 |
(175 kb.) |
| Racotumomab (1E10) |
Preclinic and mechanism of action |
2000 |
(372 kb.) |
| Racotumomab (1E10) |
Preclinical studies on antitumor properties |
2000 |
(1849 kb.) |
| GM3/VSSP |
Preclinic and mechanism of action |
2001 |
(235 kb.) |
| All |
Preclinic and mechanism of action |
2001 |
(322 kb.) |
| Racotumomab (1E10) |
Preclinic and mechanism of action |
2002 |
(304 kb.) |
| Racotumomab (1E10) |
Safety and immunogenicity in melanoma |
2002 |
(218 kb.) |
| GM3/VSSP |
Preclinic and mechanism of action |
2002 |
(485 kb.) |
| All |
Preclinic and mechanism of action |
2002 |
(150 kb.) |
| GM3/VSSP |
Safety and Immunogenicity in breast cancer patients |
2003 |
(182 kb.) |
| All |
Review |
2003 |
(241 kb.) |
| Racotumomab (1E10) |
Immune response in breast cancer patients |
2003 |
(368 kb.) |
| GM3/VSSP |
Preclinic and mechanism of action |
2004 |
(296 kb.) |
| GM3/VSSP |
Safety and inmunogenicity in melanoma |
2004 |
(3528 kb.) |
| Racotumomab (1E10) |
Safety and immunogenicity in breast cancer patients |
2006 |
(172 kb.) |
| GM3/VSSP |
Antitumor protection by perioperative immunization |
2006 |
(417 kb.) |
| GM3/VSSP |
Mechanism of action |
2007 |
(366 kb.) |
| Racotumomab (1E10) |
Safety and immunogenicity in patients with small cells lung cancer (SCLC) |
2007 |
(1282 kb.) |
| Racotumomab (1E10) |
Safety and immunogenicity in patients with non-small cells lung cancer (NSCLC) |
2007 |
(552 kb.) |
| Racotumomab (1E10) |
Characterization of the antibody response against NeuGcGM3 ganglioside in non-small cell lung cancer |
2008 |
(720 kb.) |
|
|
|
|
